OLMUTINIB

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
ATC L01EB06
UNII CHL9B67L95

Structure

InChI Key FDMQDKQUTRLUBU-UHFFFAOYSA-N
Smiles C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1
InChI
InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H26N6O2S
Molecular Weight 486.6
AlogP 5.1
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 82.62
Molecular species NEUTRAL
Aromatic Rings 4.0
Heavy Atoms 35.0

Bioactivity

Mechanism of Action Action Reference
Epidermal growth factor receptor erbB1 inhibitor INHIBITOR Other PubMed
Protein: Epidermal growth factor receptor erbB1
Description: Epidermal growth factor receptor
Organism : Homo sapiens
P00533 ENSG00000146648
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase EGFR family
- 1-2000 - - 20-104
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Met family
- - - - 7-7
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase Tec family
- 1 - - -
Assay Description Organism Bioactivity Reference
Inhibition of EGFR L858R/T790M double mutant in human NCI-H1975 cells assessed as suppression of cell proliferation Homo sapiens 10.0 nM
Inhibition of BTK (unknown origin) Homo sapiens 1.0 nM
Inhibition of EGFR exon 19 deletion and L858R mutant phosphorylation in human NCI-H1975 cells Homo sapiens 18.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 3.48 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 16.15 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 3.96 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 3.96 %
Inhibition of wild type EGFR (unknown origin) using FAM-labelled peptide as substrate at 1 uM incubated for 10 mins in presence of ATP measured by mobility shift assay Homo sapiens 20.3 %
Inhibition of EGFR T790M mutant (unknown origin) using FAM-labelled peptide as substrate at 1 uM incubated for 10 mins in presence of ATP measured by mobility shift assay Homo sapiens 98.1 %
Inhibition of c-MET (unknown origin) using FAM-labelled peptide as substrate at 1 uM incubated for 10 mins in presence of ATP measured by mobility shift assay Homo sapiens 7.1 %
Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as inhibition of cell viability at 10 uM measured after 72 hrs by MTT assay Homo sapiens 74.57 %
Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as inhibition of cell viability at 1 uM measured after 72 hrs by MTT assay Homo sapiens 6.08 %
Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as inhibition of cell viability measured after 72 hrs by MTT assay Homo sapiens 520.5 nM
Inhibition of EGFR T790M mutant (unknown origin) using FAM-labelled peptide as substrate incubated for 10 mins in presence of ATP measured by mobility shift assay Homo sapiens 48.0 nM
Inhibition of EGFR T790M/L858R double mutant (unknown origin) using FAM-labelled peptide as substrate incubated for 10 mins in presence of ATP measured by mobility shift assay Homo sapiens 12.7 nM
Antiproliferation activity against human NCI-H1975 cells harboring EGFR T790M/L858R mutation assessed as reduction in cell viability measured after 72 hrs by MTT assay Homo sapiens 520.0 nM
Inhibition of wild type EGFR (unknown origin) using FAM-labelled peptide as substrate at 1 uM incubated for 10 mins in presence of ATP by Kinase Glo luminescence assay relative to control Homo sapiens 20.3 %
Inhibition of EGFR T790M mutant (unknown origin) using FAM-labelled peptide as substrate at 1 uM incubated for 10 mins in presence of ATP by Kinase Glo luminescence assay relative to control Homo sapiens 98.1 %
Inhibition of EGFR T790M/L858R mutant (unknown origin) using FAM-labelled peptide as substrate at 1 uM incubated for 10 mins in presence of ATP by Kinase Glo luminescence assay relative to control Homo sapiens 103.6 %
Inhibition of C-MET (unknown origin) at 1 uM relative to control Homo sapiens 7.1 %
Inhibition of EGFR T790M mutant (unknown origin) using FAM-labelled peptide as substrate incubated for 10 mins fin presence of ATP by Kinase Glo luminescence assay Homo sapiens 48.0 nM
Inhibition of EGFR T790M/L858R mutant (unknown origin) using FAM-labelled peptide as substrate incubated for 10 mins in presence of ATP by Kinase Glo luminescence assay Homo sapiens 12.7 nM
Inhibition of N-terminal GST-fused human EGFR L858R/T790M double mutant cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate incubated for 20 mins by Mobility shift assay Homo sapiens 0.9 nM
Inhibition of N-terminal GST-fused human wild type EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate incubated for 20 mins by Mobility shift assay Homo sapiens 39.0 nM
Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay Homo sapiens 28.0 nM
Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Homo sapiens 26.0 nM

Cross References

Resources Reference
ChEMBL CHEMBL3786343
DrugBank DB13164
DrugCentral 5210
FDA SRS CHL9B67L95
Guide to Pharmacology 9196
PubChem 54758501
SureChEMBL SCHEMBL14914931
ZINC ZINC000198970879
CONTENTS